Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Sauzanne G KhaliliehAzher HussainDiana MontgomeryVanessa LevinePeter M ShawInga BodrugLally MekokishviliCandice Bailey-SmithXiaoli S GlasgowAmy ChengMonika MartinhoMarian IwamotoPublished in: British journal of clinical pharmacology (2018)
In subjects with moderate to severe psoriasis, tildrakizumab 200 mg did not have a discernible effect on CYP metabolism. The potential for clinically significant drug-drug interactions (DDIs) with tildrakizumab in patients with psoriasis is low. The difference in the occurrence of DDIs seen with anti-inflammatory agents in rheumatoid arthritis patients compared with psoriasis patients may be due to the much greater extent of systemic inflammation in rheumatoid arthritis as compared to psoriasis.
Keyphrases
- rheumatoid arthritis
- rheumatoid arthritis patients
- monoclonal antibody
- disease activity
- end stage renal disease
- atopic dermatitis
- anti inflammatory
- high intensity
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early onset
- emergency department
- systemic lupus erythematosus
- peritoneal dialysis
- drug induced
- patient reported outcomes
- human health
- hidradenitis suppurativa